Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study

Alessandro Parisi, Giampiero Porzio, Katia Cannita, Olga Venditti, Antonio Avallone, Roberto Filippi, Lisa Salvatore, Giampaolo Tortora, Marta Ribelli, Olga Nigro, Fabio Gelsomino, Andrea Spallanzani, Valeria Zurlo, Silvana Leo, Emanuela Dell'Aquila, Fulgenzi Claudia, Pasquale Lombardi, Susana Roselló Keränen, Giacomo Aimar, Ilaria DepetrisRiccardo Giampieri, Cristina Morelli, Michele De Tursi, Nicola Tinari, Francesca Romana Di Pietro, Federica De Galitiis, Nicoletta Zanaletti, Teresa Troiani, Pasquale Vitale, Ingrid Garajova, Michele Ghidini, Gian Paolo Spinelli, Federica Zoratto, Michela Roberto, Debora Ierino, Angelica Petrillo, Carla D'Orazio, Corrado Ficorella, Alessio Cortellini

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study'. Together they form a unique fingerprint.

Medicine & Life Sciences